NIHR Biomedical Research Centre at The Royal Marsden and the ICR shared a post on LinkedIn:
“First in Europe: Advancing melanoma treatment!
We are proud to be the first site in Europe activated for a phase 2 trial of lifileucel (tumour-infiltrating lymphocytes) in adults with advanced melanoma in November 2025.
We opened to recruitment just 41 days after HRA approval—well ahead of the national target.
Congratulations Dr. Andrew Furness and our renal, skin and solid tumor cellular therapy unit who worked tirelessly to set up this study.
This is a multicentre and open-label study of lifileucel (tumour-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma.
We can’t wait to see the impact this trial will have for patients!”
More posts about Melanoma.